Interní Med. 2002; 4(1): 7-9

Substituce testosteronu u stárnoucích hypogonadálních mužů

doc. MUDr. Ivan Kawaciuk CSc
Urologická klinika 2. LF UK a FN Motol, Praha

Keywords: PADAM-syndrome, testosterone substitution, indication, contra-indication.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kawaciuk I. Substituce testosteronu u stárnoucích hypogonadálních mužů. Interní Med. 2002;4(1):7-9.

Přibližně pětina stárnoucích mužů trpí příznaky deficitu testosteronu. Souhrnný článek se zabývá jeho diagnostikou vyplývající ze symptomatologie -PADAM- a laboratorních vyšetření. Stručně připomíná indikace k substituční léčbě testosteronem a podrobněji se zabývá jednotlivými možnostmi substituce pomocí perorálních medikamentů, intramuskulárních injekcí a transdermálních systémů a zásadami monitorování léčby. Při dodržení kontraindikací léčby byl opakovaně demonstrován její mnohostranný přínos pro stárnoucí hypogonadální muže. Obecně se jeví dlouhodobá substituční léčba jako bezpečná.

Testosterone substitution in senescent men

Nearly one fifth of all senescent men are suffering from testosterone deficiency symptomatology. The summary article deals with diagnostics of PADAM symptomatology and laboratory oufinding in conection with above named. In short a substitution therapy by testosterone is outpointed and some abilities of substitution by peroral medicaments helping is detailed. In the same way an intramuscular injection treatment, transdermal systems and monitoring principles are mentioned. On the view of contra-indications a multiply contribution in the case of such treatment was repeatly demonstrated in hypogonadal senescent men. Common is a long-term substitution treatment seen as trustworthy.

Download citation

References

  1. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab, 1997; 82 (8): 2386-2390. Go to original source... Go to PubMed...
  2. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82 (2): 407-413. Go to original source...
  3. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992, 13 (4): 297-304. Go to PubMed...
  4. Doleček R. Onemocnění z poruchy endokrinních žláz. In: Kordač a spolupracovníci: Vnitřní lékařství III, Avicenum, 1989.
  5. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989; 68: 369-373. Go to original source... Go to PubMed...
  6. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev, 1993; 2 (1): 27-32.
  7. Johnsen S, Bennett E, Jensen V. Therapeutic effectiveness of oral testosterone. Lancet, 1974; 2: 1473-1475. Go to original source... Go to PubMed...
  8. Kim YC. Testosterone supplementation in the aging male. Int J Impot Res, 1999; 11 (6): 343-352. Go to original source... Go to PubMed...
  9. Kubíček V. Racionální substituční terapie androgeny pro muže, Andrologie, 2000; (Supl.): 1-9. Go to PubMed...
  10. Lund BC, Bever-Stille KA, Perry PJ. Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy 1999; 19 (8): 951-956. Go to original source... Go to PubMed...
  11. Nieschlag E, Mauss J, Coert A, Kicovic P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol (Copenh), 1975; 79 (2): 366-374. Go to original source... Go to PubMed...
  12. Rabijewski M, Adamkiewicz M, Zgliczynski S. The influence of testosterone replacement therapy on well-being, bone mineral density and lipids in elderly men. Pol Arch Med 1998; 100 (3): 212-221.
  13. Seidman SN, Walsh BT: Testosterone and depression in aging men. Am J Geriatr Psychiatry 1999; 7 (1): 18-33. Go to original source...
  14. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51: 1335-1339. Go to original source... Go to PubMed...
  15. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000, 85 (8): 2670-2677. Go to original source...
  16. Vermeulen A. Andropause. Maturitas, 2000; 15, 34 (1): 5-15. Go to original source... Go to PubMed...
  17. Vermeulen A, Kaufman JM. Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res, 1995; 43 (1-3): 25-28. Go to original source... Go to PubMed...
  18. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab, 1996, 81 (10), 3578-3583. Go to original source... Go to PubMed...
  19. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet, 1977; 6, 2: 262-263. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.